Clinical Approach to Bleeding Between Periods

Comprehensive Practical Framework

1
Symptom Overview
Overview
2
Pathophysiology
Mechanism
3
History Taking
History
4
Physical Examination
Examination
5
Differential Diagnosis
Differential
6
Investigations
Workup
7
Clinical Decision-Making
Algorithm
8
Pearls and Pitfalls
Summary

1. Symptom Overview

Understanding the clinical significance and classification of intermenstrual bleeding

Bleeding between periods, clinically termed intermenstrual bleeding (IMB), is one of the most common gynecological complaints encountered in clinical practice. Studies indicate that approximately 10-30% of reproductive-age women experience intermenstrual bleeding at some point, accounting for roughly 20% of all gynecological consultations. This symptom carries significant clinical importance as it may represent benign hormonal fluctuations or signal serious underlying pathology including malignancy.

Definition

Intermenstrual bleeding refers to any vaginal bleeding that occurs between expected menstrual periods in a woman with an otherwise regular menstrual cycle. This is distinct from irregular menstrual bleeding patterns and should be differentiated from other sources of bleeding such as urethral, rectal, or vulvar origins. The International Federation of Gynecology and Obstetrics (FIGO) classifies this under the broader category of abnormal uterine bleeding (AUB).

Key Epidemiology

Prevalence: 10-30% of reproductive-age women experience intermenstrual bleeding
Peak incidence: Highest in the first 5 years after menarche and the perimenopausal transition
Contraceptive users: Up to 50% of hormonal contraceptive users experience breakthrough bleeding in the first 3 months
Malignancy risk: Approximately 1-10% of postmenopausal bleeding cases are due to endometrial cancer; lower in premenopausal women

Classification by Duration

Category	Duration	Common Causes	Clinical Significance
Acute/Isolated	Single episode or less than 1 month	Ovulation bleeding, missed contraceptive pills, implantation bleeding, cervical trauma	Often self-limiting; evaluate if accompanied by red flags or recurrence
Subacute/Intermittent	1 to 3 months	New hormonal contraception, cervical pathology, early pregnancy complications	Requires evaluation if persistent; consider contraceptive adjustment
Chronic/Persistent	Greater than 3 months	Structural lesions (polyps, fibroids), endometrial pathology, malignancy, chronic infection	Warrants thorough investigation including imaging and possible biopsy

Classification by Character

Light Spotting

Description: Minimal blood, often brown or pink, not requiring sanitary protection

Common causes: Ovulation bleeding (mittelschmerz), hormonal contraceptive breakthrough bleeding, cervical ectropion, implantation bleeding

Clinical implication: Often benign, especially if predictable mid-cycle; warrants investigation if new onset in older patients or associated with other symptoms

Heavy Intermenstrual Bleeding

Description: Significant bleeding requiring sanitary protection, may contain clots

Common causes: Submucosal fibroids, endometrial polyps, pregnancy complications, malignancy, coagulopathy

Clinical implication: Higher likelihood of structural pathology; requires prompt evaluation and may need urgent intervention if hemodynamically significant

Classification by Timing in Menstrual Cycle

Timing	Description	Suggests
Mid-cycle (days 12-16)	Occurs around expected ovulation	Ovulation bleeding (physiological), luteinized unruptured follicle
Pre-menstrual (days 21-28)	Occurs in the late luteal phase, just before expected period	Luteal phase defect, endometrial polyps, endometriosis, premenstrual spotting from declining progesterone
Post-menstrual (days 5-10)	Occurs shortly after menstruation ends	Residual endometrial shedding, endometrial polyps, submucosal fibroids
Random/Unpredictable	No consistent pattern in relation to cycle	Structural lesions (polyps, fibroids), cervical pathology, malignancy, anovulatory bleeding, infection
Postcoital	Occurs after sexual intercourse	Cervical ectropion, cervical polyps, cervical intraepithelial neoplasia, cervical cancer, cervicitis, vaginal atrophy

Classification by Pattern

Pattern	Description	Suggests
Cyclic/Predictable	Occurs at the same point in each menstrual cycle	Ovulation bleeding (if mid-cycle), hormonal causes, endometriosis
Acyclic/Unpredictable	Variable timing, no clear pattern	Structural pathology, malignancy, anovulation, infection
Contact-related	Provoked by intercourse or pelvic examination	Cervical lesions (ectropion, polyps, dysplasia, cancer), vaginal pathology
Medication-related	Temporally associated with starting or missing hormonal medications	Breakthrough bleeding from contraceptives, missed pills, anticoagulant therapy

The FIGO PALM-COEIN Classification System

Key Framework: The FIGO (International Federation of Gynecology and Obstetrics) developed the PALM-COEIN classification to standardize the approach to abnormal uterine bleeding, including intermenstrual bleeding:

PALM (Structural causes): Polyp, Adenomyosis, Leiomyoma (fibroid), Malignancy and hyperplasia
COEIN (Non-structural causes): Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified

This system helps clinicians systematically consider both structural and non-structural causes of bleeding between periods.

Key Concept — The “Rule Out” Priorities:

Pregnancy: Always exclude pregnancy first in any woman of reproductive age with abnormal bleeding
Malignancy: Endometrial and cervical cancer must be considered, especially in women over 40, those with risk factors, or postmenopausal women
Structural lesions: Polyps and fibroids are common and treatable causes that should be identified

2. Pathophysiology and Mechanisms

Understanding the underlying mechanisms of intermenstrual bleeding

To understand intermenstrual bleeding, one must first appreciate the intricate hormonal orchestration that maintains endometrial stability throughout the menstrual cycle. The endometrium is uniquely designed to undergo cyclical growth, maturation, and shedding under the influence of estrogen and progesterone. Any disruption to this hormonal balance, structural integrity of the reproductive tract, or vascular stability can result in bleeding outside the expected menstrual window.

The Normal Menstrual Cycle and Endometrial Stability

Phase	Days (approx.)	Dominant Hormone	Endometrial Changes	Why Bleeding Does NOT Occur
Menstrual Phase	1-5	Low estrogen and progesterone	Shedding of functional layer	Expected bleeding due to hormone withdrawal
Proliferative Phase	6-14	Rising estrogen	Endometrial proliferation, glandular growth, spiral artery development	Estrogen maintains endometrial integrity and promotes angiogenesis
Ovulation	~14	Estrogen peak, then LH surge	Follicle rupture	Brief estrogen dip may cause mid-cycle spotting in some women (physiological)
Secretory Phase	15-28	Progesterone (from corpus luteum)	Secretory transformation, decidualization, stable spiral arteries	Progesterone stabilizes endometrium, opposes estrogen-driven proliferation

Mechanisms of Intermenstrual Bleeding

Intermenstrual bleeding occurs when the normal mechanisms maintaining endometrial stability are disrupted. The major pathophysiological mechanisms include:

Hormonal Imbalance

Mechanism: Estrogen and progesterone work in balance to maintain endometrial stability. Estrogen promotes proliferation while progesterone stabilizes and transforms the endometrium.

When disrupted: Unopposed estrogen leads to disorganized proliferation and fragile vessels; low progesterone causes instability and premature shedding.

Examples: Anovulatory cycles, hormonal contraceptive breakthrough, perimenopausal fluctuations

Structural Disruption

Mechanism: Physical lesions within the uterine cavity or cervix create abnormal surfaces prone to bleeding.

When disrupted: Polyps and fibroids have fragile surface vessels; malignant lesions have disorganized, friable vasculature.

Examples: Endometrial polyps, submucosal leiomyomas, endometrial carcinoma, cervical lesions

Vascular Abnormality

Mechanism: Abnormal blood vessel formation or fragility leads to spontaneous bleeding.

When disrupted: Arteriovenous malformations, coagulopathies, or medication-induced vessel fragility cause bleeding independent of the cycle.

Examples: Anticoagulant therapy, von Willebrand disease, uterine arteriovenous malformation

Hormonal Mechanisms in Detail

Hormonal Scenario	Underlying Mechanism	Effect on Endometrium	Clinical Presentation
Estrogen withdrawal	Sudden drop in estrogen (e.g., mid-cycle ovulation, missed estrogen-containing pills)	Loss of endometrial support, focal necrosis and shedding	Light mid-cycle spotting, typically brief and self-limiting
Estrogen breakthrough	Prolonged unopposed estrogen without progesterone (anovulation)	Continued proliferation without structural support; fragile, disorganized tissue	Irregular, unpredictable bleeding; may be heavy
Progesterone withdrawal	Decline in progesterone (corpus luteum regression)	Triggers normal menstruation; premature decline causes early bleeding	Pre-menstrual spotting, shortened luteal phase
Progesterone breakthrough	Continuous progestin exposure without estrogen (progestin-only contraceptives)	Atrophic, fragile endometrium with superficial vessel exposure	Irregular spotting, common with progestin-only methods
Altered estrogen-to-progesterone ratio	Imbalance in the ratio during hormonal contraceptive use	Inadequate endometrial stabilization despite hormone presence	Breakthrough bleeding, especially in first 3 months of new contraceptive

How Specific Conditions Cause Intermenstrual Bleeding

Condition	Mechanism	Clinical Implication
Endometrial polyps	Localized overgrowth of endometrial tissue with fragile surface vessels that bleed easily; may outgrow their blood supply	Usually present with irregular spotting; removal is curative
Submucosal leiomyomas (fibroids)	Distort the endometrial cavity, stretch overlying endometrium, and compress blood vessels leading to venous congestion and surface erosion	Often cause heavy bleeding; location more important than size
Adenomyosis	Endometrial glands within myometrium disrupt normal myometrial contraction and vessel control; altered local prostaglandin production	May cause both heavy menstrual bleeding and intermenstrual bleeding
Cervical ectropion	Columnar epithelium extends onto ectocervix, which is more fragile than squamous epithelium and bleeds easily with contact	Common cause of postcoital bleeding; often benign but must rule out dysplasia
Endometrial hyperplasia	Excessive estrogen stimulation leads to abnormal endometrial thickening with disorganized glands and unstable vasculature	Important to diagnose as it may progress to endometrial carcinoma
Endometrial carcinoma	Malignant tissue with abnormal angiogenesis, fragile tumor vessels, and tissue necrosis	Must be excluded in all women over 40 with new intermenstrual bleeding or those with risk factors
Cervical cancer	Malignant transformation with abnormal, friable vessels; often presents with contact bleeding	Critical to exclude, especially in those overdue for cervical screening
Chronic endometritis	Chronic inflammation disrupts endometrial integrity and local hemostasis; often associated with plasma cell infiltration	May be subtle; consider in unexplained intermenstrual bleeding or infertility
Hormonal contraceptive breakthrough	Exogenous hormones alter the endometrial balance; progestins cause atrophic, fragile endometrium; low estrogen component inadequate for stability	Common in first 3 months; usually resolves; consider different formulation if persistent
Ovulation bleeding	Mid-cycle estrogen dip following the pre-ovulatory peak temporarily withdraws endometrial support	Physiological; light spotting with mild pelvic discomfort (mittelschmerz)
Implantation bleeding	Blastocyst implantation disrupts superficial endometrial vessels approximately 6-12 days after fertilization	Light spotting, may be mistaken for early period; occurs before expected menses

Local Endometrial Factors

Prostaglandins and Vasoactive Mediators

Role: Prostaglandins (especially prostaglandin F2α and E2) regulate endometrial blood flow and myometrial contraction.

In normal menstruation: Prostaglandin release triggers vasoconstriction of spiral arteries, leading to ischemia and controlled shedding.

When disrupted: Imbalanced prostaglandin production (e.g., in adenomyosis, fibroids) leads to abnormal bleeding patterns.

Matrix Metalloproteinases (MMPs)

Role: MMPs break down the extracellular matrix during menstruation, allowing tissue shedding.

Normal regulation: MMPs are tightly controlled by tissue inhibitors (TIMPs) and hormonal signals.

When disrupted: Excessive MMP activity causes premature or excessive tissue breakdown, contributing to abnormal bleeding.

Vascular Factors and Hemostasis

Factor	Normal Function	When Abnormal
Spiral arteries	Specialized vessels that constrict to stop bleeding during menstruation	Abnormal development in polyps/fibroids; impaired constriction leads to prolonged bleeding
Endometrial hemostasis	Local clotting factors and platelet aggregation control bleeding	Coagulopathies (von Willebrand disease, platelet disorders) impair hemostasis
Angiogenesis	Controlled new vessel formation during endometrial regeneration	Disorganized angiogenesis in malignancy creates fragile, bleeding-prone vessels

Often Overlooked Mechanism: Chronic Endometritis

Chronic endometritis is an underdiagnosed cause of intermenstrual bleeding. It results from persistent low-grade infection (often polymicrobial) that disrupts normal endometrial function. The inflammation alters local hemostasis, increases vascular fragility, and prevents normal endometrial cycling. It should be considered in women with unexplained intermenstrual bleeding, especially those with a history of pelvic inflammatory disease, intrauterine device use, or infertility. Diagnosis requires endometrial biopsy showing plasma cell infiltration, and treatment with antibiotics (typically doxycycline) is often curative.

Pregnancy-Related Mechanisms

Always Consider Pregnancy Complications

In any reproductive-age woman with intermenstrual bleeding, pregnancy must be excluded first. Pregnancy-related causes of bleeding include:

Implantation bleeding: Light spotting 6-12 days post-fertilization as blastocyst implants
Threatened miscarriage: Bleeding with closed cervix; pregnancy may continue
Inevitable/incomplete miscarriage: Bleeding with cervical dilation; pregnancy loss occurring
Ectopic pregnancy: Bleeding from decidual shedding due to inadequate hormonal support from abnormally located pregnancy — a gynecological emergency
Gestational trophoblastic disease: Abnormal trophoblastic tissue with high β-hCG and characteristic bleeding

3. History Taking

A comprehensive approach to eliciting the intermenstrual bleeding history

Red Flags — Require Urgent Evaluation

Postmenopausal bleeding — Endometrial cancer until proven otherwise
Heavy bleeding with hemodynamic instability — Requires urgent stabilization
Positive pregnancy test with bleeding — Ectopic pregnancy must be excluded
Bleeding with pelvic pain and fever — Pelvic inflammatory disease, tubo-ovarian abscess

New intermenstrual bleeding in women over 40 — Higher malignancy risk
Persistent postcoital bleeding — Cervical pathology including cancer
Bleeding with significant weight loss — Malignancy, systemic disease
Known bleeding disorder with uncontrolled bleeding — Hematology consultation

First Question — Always Rule Out Pregnancy

Before proceeding with detailed history, establish pregnancy status in every woman of reproductive age. Ask: “Is there any chance you could be pregnant? When was your last menstrual period? Are you using contraception consistently?” A urine or serum β-hCG should be obtained regardless of the answer, as patients may be unaware of early pregnancy.

Systematic History: The “BLEEDS” Approach

Use the mnemonic “BLEEDS” to ensure comprehensive history taking for intermenstrual bleeding:

B — Bleeding characteristics: Amount (light spotting versus heavy, number of pads/tampons), color (bright red, dark, brown), duration of episodes, presence of clots
L — Last menstrual period and cycle pattern: Date of last normal period, usual cycle length and regularity, how this bleeding differs from normal menses
E — Events and triggers: Relation to intercourse (postcoital), timing in cycle (mid-cycle, premenstrual), relation to physical activity, recent procedures
E — Exposures and medications: Contraceptive use (type, compliance, recent changes), hormone therapy, anticoagulants, herbal supplements
D — Duration and development: When did this start? Single episode or recurrent? Progressive or stable? Previous similar episodes?
S — Symptoms associated: Pain (pelvic, during intercourse), discharge, fever, urinary symptoms, bowel symptoms, systemic symptoms (weight loss, fatigue)

Key History Elements in Detail

Menstrual History

Element	What to Ask	Why It Matters
Last menstrual period	“When was the first day of your last normal period?”	Establishes cycle day, helps identify if bleeding is truly intermenstrual, pregnancy dating
Cycle regularity	“Are your periods regular? How many days between periods?”	Irregular cycles suggest anovulation; regular cycles make structural causes more likely
Normal menstrual flow	“How heavy are your normal periods? How many days do they last?”	Baseline for comparison; heavy menses with intermenstrual bleeding suggests fibroids
Menarche and menstrual history	“At what age did you start your periods? Have you ever had irregular bleeding before?”	Early menarche increases estrogen exposure; history of irregularity suggests chronic issue

Targeted Questions by Suspected Cause

Suspected Cause	Key Features	Ask This Question
Pregnancy-related	Missed period, breast tenderness, nausea, unprotected intercourse	“Is there any possibility you could be pregnant? Have you had unprotected intercourse?”
Ectopic pregnancy	Unilateral pelvic pain, vaginal bleeding, positive pregnancy test	“Do you have pain on one side of your pelvis? Any shoulder tip pain or dizziness?”
Hormonal contraceptive breakthrough	Recent start or change of contraception, missed pills	“Have you recently started or changed your contraceptive? Have you missed any pills?”
Ovulation bleeding	Predictable mid-cycle spotting, mild pelvic discomfort	“Does the spotting happen around the middle of your cycle each month? Any cramping at the same time?”
Endometrial polyps	Irregular spotting, may be postcoital, often in perimenopausal women	“Is the bleeding unpredictable? Does it happen after intercourse?”
Uterine fibroids	Heavy periods with intermenstrual spotting, pelvic pressure, urinary frequency	“Are your periods heavier than they used to be? Do you feel pressure in your pelvis or need to urinate frequently?”
Cervical ectropion or pathology	Postcoital bleeding, increased vaginal discharge	“Does bleeding occur after intercourse? Have you noticed increased vaginal discharge?”
Cervical cancer	Postcoital bleeding, foul discharge, risk factors (smoking, HPV, no screening)	“When was your last cervical smear? Have you ever had an abnormal smear result?”
Endometrial cancer/hyperplasia	Postmenopausal bleeding, obesity, unopposed estrogen, diabetes	“Have you experienced any bleeding after menopause? Do you have diabetes or high blood pressure?”
Infection (cervicitis, endometritis, pelvic inflammatory disease)	Abnormal discharge, pelvic pain, fever, dyspareunia	“Do you have any unusual vaginal discharge? Any pain during intercourse or pelvic pain?”
Coagulopathy	Easy bruising, prolonged bleeding from cuts, heavy periods since menarche, family history	“Do you bruise easily? Do cuts take a long time to stop bleeding? Have your periods always been very heavy?”
Intrauterine device-related	Bleeding following insertion, irregular spotting (especially with hormonal intrauterine device)	“Do you have an intrauterine device? When was it inserted? Can you feel the strings?”

Sexual and Reproductive History

Sexual History

Sexual activity: Currently sexually active? New partner?
Contraception: Type, duration, compliance
Postcoital bleeding: Does bleeding occur after intercourse?
Dyspareunia: Pain during intercourse (suggests infection, endometriosis)
Sexually transmitted infection risk: Multiple partners, unprotected intercourse, previous infections

Reproductive History

Gravidity and parity: Previous pregnancies, outcomes
Pregnancy intentions: Trying to conceive? Recent pregnancy?
Previous gynecological procedures: Dilatation and curettage, cone biopsy, loop excision
Fertility issues: History of infertility, recurrent pregnancy loss (suggests chronic endometritis)
Cervical screening history: Last smear, previous abnormal results, colposcopy

Medication and Iatrogenic Causes

Medications That Cause Intermenstrual Bleeding

Combined oral contraceptives — Breakthrough bleeding, especially in first 3 months or with missed pills
Progestin-only contraceptives — Irregular bleeding is common and expected (pills, implant, injection, hormonal intrauterine device)
Anticoagulants — Warfarin, direct oral anticoagulants, heparin increase bleeding
Antiplatelet agents — Aspirin, clopidogrel
Selective serotonin reuptake inhibitors (SSRIs) — Impair platelet function
Hormone replacement therapy — Breakthrough bleeding, especially in early use
Tamoxifen — Increases endometrial polyps, hyperplasia, cancer risk
Corticosteroids — Long-term use affects menstrual cycle
Herbal supplements — Ginseng, soy, black cohosh have estrogenic effects

Questions About Medications

“What medications are you currently taking, including over-the-counter and supplements?”
“Have you recently started any new medications?”
“Are you taking any blood thinners?”
“What type of contraception do you use? How long have you been using it?”
“Have you missed any contraceptive pills recently?”
“Have you recently changed your contraceptive method or dose?”
“Are you taking any herbal remedies or supplements?”

Past Medical and Family History

Past Medical History

Gynecological conditions: Known fibroids, polyps, endometriosis, polycystic ovary syndrome
Previous gynecological surgery: Myomectomy, polypectomy, hysteroscopy, cone biopsy
Bleeding disorders: Von Willebrand disease, platelet disorders, clotting factor deficiencies
Thyroid disease: Both hypothyroidism and hyperthyroidism affect menstruation
Liver disease: Impairs estrogen metabolism and clotting factor production
Chronic conditions: Diabetes, obesity, hypertension (endometrial cancer risk factors)

Family History

Bleeding disorders: Von Willebrand disease, hemophilia (suggests inherited coagulopathy)
Gynecological cancers: Endometrial, ovarian, cervical, breast cancer
Lynch syndrome: Family history of colorectal, endometrial, ovarian cancers at young age
Uterine fibroids: Tend to run in families, especially in women of African descent
Polycystic ovary syndrome: May have familial clustering

Social and Lifestyle History

Factor	Relevance	What to Ask
Smoking	Risk factor for cervical cancer and dysplasia; affects estrogen metabolism; reduces contraceptive efficacy	“Do you smoke? How many cigarettes per day?”
Alcohol	Affects liver function and estrogen metabolism; heavy use associated with menstrual irregularities	“How much alcohol do you drink per week?”
Body weight	Obesity increases estrogen through peripheral conversion; risk factor for anovulation and endometrial cancer	“Has your weight changed significantly recently?”
Stress and exercise	Extreme stress or exercise can cause anovulation and irregular bleeding	“Have you been under significant stress? Do you exercise intensively?”
Occupation	Shift work can disrupt menstrual cycles; some occupations have chemical exposures	“What is your occupation? Do you work shifts?”

4. Physical Examination

A systematic approach for evaluating intermenstrual bleeding

Systematic Framework: Use a “General to Specific” approach — begin with general assessment and vital signs, then proceed to abdominal examination, and finally pelvic examination. Always ensure privacy, obtain consent, offer a chaperone, and explain each step to the patient.

General Inspection

Appearance and body habitus: Obesity (endometrial cancer risk, anovulation), cachexia (malignancy), hirsutism and acne (polycystic ovary syndrome)
Signs of anemia: Pallor of conjunctivae, mucous membranes, nail beds (suggests chronic or heavy blood loss)
Signs of bleeding disorder: Petechiae, ecchymoses, bruising (coagulopathy)
Thyroid: Goiter, exophthalmos, tremor, bradycardia (thyroid dysfunction affects menstruation)
Signs of hyperandrogenism: Hirsutism, acne, male-pattern hair loss (polycystic ovary syndrome, androgen-secreting tumor)
Acanthosis nigricans: Velvety hyperpigmentation in skin folds (insulin resistance, polycystic ovary syndrome)

Vital Signs

Vital Sign	What to Look For	Clinical Significance
Heart rate	Tachycardia (greater than 100 beats per minute)	May indicate significant blood loss, anemia, infection, ectopic pregnancy with hemorrhage
Blood pressure	Hypotension, orthostatic changes	Suggests hemodynamic compromise from blood loss; urgent intervention needed
Temperature	Fever (greater than 38°C)	Suggests infection: pelvic inflammatory disease, endometritis, septic abortion
Respiratory rate	Tachypnea	May indicate anemia, metabolic acidosis from significant hemorrhage
Body mass index	Obesity (BMI greater than 30) or underweight (BMI less than 18.5)	Obesity: anovulation, endometrial cancer risk; underweight: hypothalamic amenorrhea

Abdominal Examination

Inspection

Distension: May indicate large fibroid uterus, ascites (ovarian malignancy), pregnancy
Visible masses: Large fibroids may be visible as lower abdominal bulge
Surgical scars: Previous cesarean section, laparoscopy, laparotomy
Striae: May indicate rapid weight changes, Cushing syndrome

Palpation

Tenderness: Suprapubic tenderness (infection, ectopic pregnancy), rebound tenderness (peritonitis)
Masses: Palpable uterus (fibroids, pregnancy beyond 12 weeks), adnexal masses
Guarding and rigidity: Suggests peritoneal irritation (ruptured ectopic, tubo-ovarian abscess)
Hepatomegaly: Liver disease affecting estrogen metabolism and coagulation
Lymphadenopathy: Inguinal lymph nodes (infection, malignancy)

Percussion and Auscultation

Shifting dullness: Ascites may indicate ovarian malignancy
Bowel sounds: Absent or hypoactive in peritonitis

Pelvic Examination

Before Proceeding

Ensure the patient has emptied her bladder. Obtain informed consent and offer a chaperone. Position the patient in lithotomy or left lateral position. Ensure adequate lighting and warm speculum. Explain each step before performing it.

External Genital Inspection

Vulva: Lesions, ulcers, warts, atrophy, excoriation, signs of trauma
Urethral meatus: Caruncle, prolapse, discharge (urethral source of bleeding)
Vaginal introitus: Bleeding, discharge, lesions, atrophy
Perineum and perianal area: Hemorrhoids, fissures (rectal source of bleeding)

Speculum Examination

Structure	What to Assess	Abnormal Findings and Their Significance
Vaginal walls	Color, lesions, discharge, foreign bodies, atrophy	Atrophy (hypoestrogenic state), lesions (trauma, malignancy), retained tampon or foreign body
Cervix	Position, size, shape, surface, os	Ectropion (red granular area around os), polyps protruding from os, nabothian cysts, contact bleeding
Cervical lesions	Ulceration, mass, friable tissue, bleeding on touch	Visible mass suggests cervical cancer; friability may indicate infection, dysplasia, or malignancy
Cervical os	Open or closed, products of conception, polyps	Open os with products of conception (inevitable/incomplete miscarriage); polyp visible at os
Discharge	Color, consistency, odor	Purulent (infection), blood-stained (cervical pathology), foul-smelling (bacterial vaginosis, malignancy)
Intrauterine device strings	Visible and appropriate length	Missing strings may indicate expulsion, perforation, or pregnancy
Active bleeding	Source: cervical os, cervical surface, vaginal walls	Identify the source of bleeding; blood coming from os suggests uterine source

Cervical Examination Technique

Carefully inspect the entire cervix by rotating the speculum. Note the transformation zone (junction between squamous and columnar epithelium). Use a swab to gently clear blood or discharge to visualize the cervix properly. If a lesion is seen, do not take a smear — instead, refer urgently for colposcopy. Take swabs for infection screening (chlamydia, gonorrhea) if indicated.

Bimanual Examination

Structure	What to Assess	Abnormal Findings
Cervix	Position, consistency, mobility, tenderness	Cervical motion tenderness (pelvic inflammatory disease, ectopic pregnancy); fixed cervix (malignancy, endometriosis)
Uterus — size	Normal size is approximately 8 cm (size of a small pear)	Enlarged: fibroids (irregular, firm), adenomyosis (globular, tender), pregnancy
Uterus — contour	Regular or irregular	Irregular contour suggests fibroids; smooth enlargement suggests adenomyosis or pregnancy
Uterus — mobility	Mobile or fixed	Fixed uterus suggests endometriosis, adhesions, or malignancy with parametrial involvement
Uterus — tenderness	Tenderness on palpation	Tender uterus suggests infection (endometritis), adenomyosis, or pregnancy complication
Adnexa	Masses, tenderness	Adnexal mass (ovarian cyst, ectopic pregnancy, tubo-ovarian abscess); tenderness (infection, ectopic)
Pouch of Douglas	Nodularity, tenderness, fullness	Nodularity (endometriosis); fullness and tenderness (blood, pus, or fluid collection)

Expected Findings by Etiology

Condition	General Examination	Abdominal Examination	Pelvic Examination
Cervical ectropion	Usually normal	Normal	Red, granular area around cervical os; bleeds easily on contact
Cervical polyp	Usually normal	Normal	Smooth, red polyp protruding from cervical os
Cervical cancer	May have cachexia, lymphadenopathy in advanced cases	Usually normal; may have inguinal lymphadenopathy	Visible cervical lesion (ulcer, mass, friable tissue); contact bleeding; fixed cervix in advanced disease
Uterine fibroids	Usually normal; may have pallor if anemic	May have palpable mass arising from pelvis	Enlarged, irregular, firm, mobile uterus; submucous fibroid may be visible at os
Endometrial polyp	Usually normal	Normal	Usually normal; occasionally polyp protrudes through cervical os
Endometrial cancer	May be obese; pallor if anemic	Usually normal	Often normal; may have blood at os; enlarged uterus in advanced disease
Pelvic inflammatory disease	May appear unwell, febrile	Lower abdominal tenderness, guarding	Purulent discharge, cervical motion tenderness, adnexal tenderness, possible adnexal mass
Ectopic pregnancy	May be pale, tachycardic, hypotensive	Lower abdominal tenderness, guarding if ruptured	Cervical motion tenderness, adnexal tenderness or mass, uterus may be slightly enlarged
Hormonal contraceptive breakthrough	Normal	Normal	Normal; intrauterine device strings visible if present
Polycystic ovary syndrome	Obesity, hirsutism, acne, acanthosis nigricans	Central adiposity	Usually normal; may have enlarged ovaries
Coagulopathy	Petechiae, ecchymoses, bruising	Hepatosplenomegaly in some conditions	Usually normal

Important Teaching Point

Normal examination is common! Many causes of intermenstrual bleeding present with entirely normal physical examination findings. This includes endometrial polyps (unless protruding), small fibroids, hormonal breakthrough bleeding, ovulation bleeding, chronic endometritis, and early endometrial pathology. A normal examination does not exclude significant pathology and should not prevent further investigation — particularly in women over 40, those with persistent symptoms, or those with risk factors for malignancy. Transvaginal ultrasound and/or endometrial biopsy may be required even when examination is unremarkable.

5. Differential Diagnosis

Systematic approach organized by probability, age, and clinical features

The differential diagnosis of intermenstrual bleeding is broad and varies significantly by age, reproductive status, and clinical context. A systematic approach using the FIGO PALM-COEIN classification helps ensure no important cause is overlooked. Always consider pregnancy first in any woman of reproductive age.

Step-by-Step Approach to Intermenstrual Bleeding:

Step 1: Rule out pregnancy — obtain β-hCG in all reproductive-age women
Step 2: Identify red flags requiring urgent evaluation (hemodynamic instability, postmenopausal bleeding, suspicious cervical lesion)
Step 3: Consider the patient’s age and menopausal status — this significantly changes the differential
Step 4: Review medications and contraceptive use — iatrogenic causes are very common
Step 5: Apply the PALM-COEIN framework to systematically consider structural and non-structural causes

Reproductive Age Women (18-40 years)

Probability	Condition	Key Features	Red Flags
COMMON (approximately 60-70%)	Hormonal contraceptive breakthrough bleeding	Recent start or change of contraception, missed pills, first 3 months of use	None typically; exclude pregnancy if pills missed
COMMON	Ovulation bleeding (mittelschmerz)	Predictable mid-cycle spotting, mild unilateral pelvic discomfort, light and brief	None — physiological
COMMON	Cervical ectropion	Postcoital bleeding, increased discharge, visible red area around cervical os	Must exclude cervical dysplasia/cancer
COMMON	Pregnancy-related (implantation, threatened miscarriage)	Positive pregnancy test, light spotting, may have cramping	Heavy bleeding, severe pain, hemodynamic instability
LESS COMMON (approximately 20-30%)	Endometrial polyps	Irregular spotting, postcoital bleeding, may be asymptomatic	Postmenopausal; risk of malignant change
LESS COMMON	Uterine fibroids (leiomyomas)	Heavy periods, intermenstrual bleeding, pelvic pressure, enlarged irregular uterus	Rapid growth, postmenopausal growth
LESS COMMON	Cervicitis and sexually transmitted infections	Abnormal discharge, postcoital bleeding, dyspareunia, pelvic pain	Fever, severe pelvic pain (pelvic inflammatory disease)
LESS COMMON	Cervical polyps	Postcoital bleeding, visible polyp at cervical os	Usually benign but should be removed and sent for histology
LESS COMMON	Ectopic pregnancy	Unilateral pelvic pain, vaginal bleeding, positive pregnancy test	Hemodynamic instability, shoulder tip pain — surgical emergency
UNCOMMON BUT SERIOUS (approximately 5-10%)	Cervical intraepithelial neoplasia or cervical cancer	Postcoital bleeding, abnormal discharge, visible cervical lesion	Friable cervical mass, foul discharge, weight loss
UNCOMMON BUT SERIOUS	Coagulopathy (von Willebrand disease, platelet disorders)	Heavy periods since menarche, easy bruising, family history	Severe bleeding, other bleeding manifestations
UNCOMMON BUT SERIOUS	Chronic endometritis	Subtle irregular bleeding, infertility, history of pelvic inflammatory disease or intrauterine procedures	Associated infertility, recurrent pregnancy loss

Perimenopausal Women (40-50 years)

Probability	Condition	Approximate Frequency	Key Distinguishing Features
COMMON	Anovulatory bleeding (dysfunctional uterine bleeding)	30-40%	Irregular cycles, variable flow, no structural abnormality on imaging
COMMON	Endometrial polyps	20-30%	Irregular spotting, visible on ultrasound or hysteroscopy
COMMON	Uterine fibroids	20-30%	Heavy periods, enlarged uterus, may have pressure symptoms
LESS COMMON	Adenomyosis	10-15%	Dysmenorrhea, heavy bleeding, globular tender uterus
LESS COMMON	Endometrial hyperplasia	5-10%	Obesity, anovulation, thickened endometrium on ultrasound
UNCOMMON BUT MUST EXCLUDE	Endometrial carcinoma	1-5%	Risk factors (obesity, diabetes, nulliparity, tamoxifen), persistent bleeding
UNCOMMON BUT MUST EXCLUDE	Cervical carcinoma	1-2%	Postcoital bleeding, abnormal cervix on examination, overdue screening

Postmenopausal Women (over 50 years or more than 12 months since last period)

Critical Principle

All postmenopausal bleeding must be considered endometrial cancer until proven otherwise. Approximately 10% of postmenopausal bleeding is due to endometrial cancer. All women with postmenopausal bleeding require investigation including transvaginal ultrasound and consideration of endometrial biopsy.

Probability	Condition	Approximate Frequency	Key Features
COMMON	Atrophic vaginitis	30-40%	Thin, pale vaginal epithelium; spotting, dyspareunia, discharge
COMMON	Endometrial atrophy	20-30%	Thin endometrium (less than 4 mm) on ultrasound, scant bleeding
LESS COMMON	Endometrial polyps	10-20%	Focal thickening on ultrasound, may be seen on saline infusion sonography
LESS COMMON	Hormone replacement therapy-related bleeding	10-15%	Temporal relationship with hormone therapy use
MUST EXCLUDE	Endometrial carcinoma	5-10%	Thickened endometrium (greater than 4 mm), risk factors
MUST EXCLUDE	Endometrial hyperplasia	5-10%	Precursor to carcinoma; requires histological diagnosis
UNCOMMON	Cervical carcinoma	1-2%	Abnormal cervical appearance, contact bleeding

Anatomical Approach to Differential Diagnosis

Uterine Corpus

Endometrial polyps

Submucosal fibroids

Adenomyosis

Endometrial hyperplasia

Endometrial carcinoma

Chronic endometritis

Intrauterine device-related

Arteriovenous malformation

Cervix

Cervical ectropion

Cervical polyps

Cervicitis

Cervical intraepithelial neoplasia

Cervical carcinoma

Cervical trauma

Nabothian cysts (rarely bleed)

Vagina and Vulva

Atrophic vaginitis

Vaginal trauma

Vaginal infection

Vaginal cancer (rare)

Foreign body

Vulvar lesions

Systemic and Hormonal

Anovulatory bleeding

Coagulopathy

Thyroid dysfunction

Hyperprolactinemia

Polycystic ovary syndrome

Medication-induced

Pregnancy-related

FIGO PALM-COEIN Classification

Category	Cause	Key Features	Primary Investigation
PALM (Structural)	Polyp (endometrial or cervical)	Irregular bleeding, postcoital, visible on imaging or examination	Transvaginal ultrasound, saline infusion sonography, hysteroscopy
	Adenomyosis	Dysmenorrhea, heavy bleeding, globular tender uterus	Transvaginal ultrasound, MRI
	Leiomyoma (fibroid)	Heavy periods, pressure symptoms, enlarged irregular uterus	Transvaginal ultrasound
	Malignancy and hyperplasia	Risk factors, persistent bleeding, postmenopausal bleeding	Endometrial biopsy, hysteroscopy
COEIN (Non-structural)	Coagulopathy	Heavy bleeding since menarche, bruising, family history	Complete blood count, coagulation studies, von Willebrand panel
	Ovulatory dysfunction	Irregular cycles, features of polycystic ovary syndrome, perimenopausal	Hormone levels (follicle-stimulating hormone, luteinizing hormone, estradiol, progesterone)
	Endometrial (primary disorder)	Diagnosis of exclusion, may have chronic endometritis	Endometrial biopsy
	Iatrogenic	Hormonal contraceptives, anticoagulants, hormone replacement therapy	Medication review
	Not yet classified	Rare causes, arteriovenous malformation, myometrial hypertrophy	Advanced imaging, specialist referral

Drug-Induced Intermenstrual Bleeding

Drug or Drug Class	Mechanism	Characteristics	Management
Combined oral contraceptives	Inadequate estrogen for endometrial stability; missed pills cause hormone withdrawal	Common in first 3 months; light spotting; related to missed pills	Reassurance if new; consider higher estrogen formulation if persistent; exclude other causes
Progestin-only pills	Atrophic, fragile endometrium without estrogen support	Irregular spotting common and expected; unpredictable pattern	Counseling; may improve over time; consider alternative method if unacceptable
Levonorgestrel intrauterine device	Local progestin effect causing endometrial atrophy	Irregular spotting common in first 3-6 months; usually decreases over time	Reassurance; bleeding typically improves; exclude malposition or infection
Copper intrauterine device	Local inflammatory response; no hormonal effect	Heavier periods; intermenstrual spotting less common than with hormonal intrauterine device	Rule out malposition, infection, or expulsion
Depot medroxyprogesterone acetate (injection)	Continuous progestin causing endometrial atrophy	Irregular bleeding common initially; may progress to amenorrhea	Counseling; bleeding often improves with continued use
Etonogestrel implant	Continuous progestin causing variable endometrial effects	Unpredictable bleeding pattern; most common reason for discontinuation	Counseling; short course of combined pill may help
Anticoagulants (warfarin, direct oral anticoagulants, heparin)	Impaired hemostasis allows bleeding from minor endometrial disruption	May unmask underlying pathology; heavier and prolonged bleeding	Investigate for underlying cause; liaise with anticoagulation service
Antiplatelet agents (aspirin, clopidogrel)	Impaired platelet function	May increase bleeding from any cause	Investigate for underlying pathology
Selective serotonin reuptake inhibitors	Impair platelet aggregation via serotonin effects	May increase menstrual and intermenstrual bleeding	Consider if temporal relationship; investigate other causes
Tamoxifen	Partial estrogen agonist effect on endometrium; increases polyps, hyperplasia, cancer risk	Any bleeding on tamoxifen requires investigation	Transvaginal ultrasound and endometrial biopsy mandatory
Hormone replacement therapy	Endometrial stimulation; breakthrough bleeding with continuous regimens	Unscheduled bleeding on hormone replacement therapy needs evaluation	Investigate to exclude endometrial pathology
Corticosteroids (chronic use)	Affects hypothalamic-pituitary-ovarian axis	Menstrual irregularity, anovulation	Address underlying condition requiring steroids

Quick Reference: “If You See This, Think This”

Clinical Clue	Think This First	Next Step
Positive pregnancy test with bleeding	Threatened miscarriage, ectopic pregnancy	Urgent transvaginal ultrasound, serial β-hCG
Postmenopausal bleeding	Endometrial cancer until proven otherwise	Transvaginal ultrasound, endometrial biopsy
Postcoital bleeding with visible cervical lesion	Cervical cancer	Urgent colposcopy referral (do not take smear)
Mid-cycle spotting, predictable each month	Ovulation bleeding (physiological)	Reassurance if pattern consistent; consider ultrasound if uncertain
Bleeding after starting new contraceptive	Breakthrough bleeding (iatrogenic)	Reassurance; review in 3 months; exclude missed pills
Heavy periods with intermenstrual bleeding, enlarged uterus	Uterine fibroids	Transvaginal ultrasound
Irregular bleeding with obesity, hirsutism, irregular cycles	Polycystic ovary syndrome with anovulation	Hormone levels, ultrasound, consider endometrial protection
Purulent discharge, pelvic pain, cervical motion tenderness	Pelvic inflammatory disease	Swabs for infection, empiric antibiotics
Heavy bleeding since menarche, easy bruising	Coagulopathy (von Willebrand disease)	Coagulation studies, von Willebrand panel, hematology referral
Bleeding on tamoxifen	Endometrial pathology (polyp, hyperplasia, cancer)	Mandatory transvaginal ultrasound and endometrial biopsy
Unexplained bleeding with infertility history	Chronic endometritis	Endometrial biopsy looking for plasma cells

6. Diagnostic Investigations

A stepwise, cost-effective approach guided by clinical suspicion

Investigation of intermenstrual bleeding should be tailored to the patient’s age, risk factors, and clinical presentation. A stepwise approach beginning with basic investigations and progressing to more specialized tests based on initial findings is most cost-effective.

First-Line Investigations for All Patients

Investigation	Purpose	What to Look For	Practical Points
Urine or serum β-hCG	Exclude pregnancy	Positive result requires pregnancy-related workup	Mandatory in all reproductive-age women regardless of contraceptive use or stated sexual activity
Complete blood count	Assess for anemia, thrombocytopenia	Hemoglobin less than 120 g/L (anemia); low platelets (bleeding risk)	Guides need for iron supplementation; severe anemia may need transfusion
Cervical screening (if due)	Screen for cervical dysplasia or cancer	Abnormal cytology or positive high-risk HPV	Do NOT take smear if visible cervical lesion — refer directly for colposcopy
Infection screening	Detect sexually transmitted infections	Chlamydia, gonorrhea (nucleic acid amplification test)	Offer to all sexually active women; treat partners if positive
Transvaginal ultrasound	Assess uterine and ovarian structure	Endometrial thickness, polyps, fibroids, ovarian pathology	First-line imaging; best performed in proliferative phase (days 5-10) for endometrial assessment

Transvaginal Ultrasound: Key Findings and Interpretation

Finding	Normal Values	Abnormal Findings	Clinical Significance
Endometrial thickness (premenopausal)	Varies with cycle: 2-4 mm (menstrual), up to 14 mm (secretory)	Thickened, irregular, or heterogeneous endometrium	Consider polyp, hyperplasia, or malignancy if abnormal
Endometrial thickness (postmenopausal)	Less than or equal to 4 mm (not on hormone replacement therapy)	Greater than 4 mm or any focal thickening	Requires endometrial sampling to exclude malignancy
Endometrial polyp	None	Focal echogenic lesion within endometrial cavity, often with feeding vessel on Doppler	Hysteroscopic removal recommended for diagnosis and treatment
Uterine fibroids	None	Well-defined hypoechoic masses; note location (submucosal, intramural, subserosal)	Submucosal fibroids most likely to cause intermenstrual bleeding
Adenomyosis	Homogeneous myometrium	Heterogeneous myometrium, asymmetric wall thickening, myometrial cysts, poor definition of endometrial-myometrial junction	May coexist with fibroids; MRI more accurate if diagnosis uncertain
Intrauterine device position	Fundal position	Low-lying, embedded, or absent	Malposition may cause bleeding; absent device needs plain radiograph to distinguish expulsion from perforation

Targeted Investigations by Clinical Suspicion

If Suspecting Endometrial Pathology (Polyp, Hyperplasia, Malignancy)

First-Line Tests

Transvaginal ultrasound: Endometrial thickness greater than 4 mm postmenopausal, focal lesions, heterogeneous endometrium
Endometrial biopsy (Pipelle): Outpatient sampling; sensitivity approximately 90% for endometrial cancer in postmenopausal women

Second-Line Tests

Saline infusion sonohysterography: Better visualization of focal lesions (polyps, submucosal fibroids)
Hysteroscopy with directed biopsy: Gold standard for diagnosing and treating intrauterine pathology; can remove polyps

If Suspecting Cervical Pathology

First-Line Tests

Speculum examination: Visualize cervix for ectropion, polyps, lesions
Cervical smear: If no visible lesion and screening is due
Infection screening: Chlamydia and gonorrhea nucleic acid amplification test

Second-Line Tests

Colposcopy: If abnormal smear, visible lesion, or persistent postcoital bleeding; allows directed biopsy
Cervical biopsy: If suspicious lesion seen — do NOT take smear, refer directly

If Suspecting Pregnancy-Related Cause

First-Line Tests

Serum β-hCG: Quantitative level helps assess pregnancy viability and location
Transvaginal ultrasound: Locate pregnancy (intrauterine versus extrauterine), assess viability

Second-Line Tests

Serial β-hCG (48-72 hours): Doubling time helps assess viability; slower rise suggests ectopic or failing pregnancy
Progesterone level: Low progesterone (less than 25 nmol/L) associated with non-viable pregnancy

If Suspecting Hormonal or Ovulatory Dysfunction

First-Line Tests

Day 21 progesterone: Greater than 30 nmol/L confirms ovulation; low level suggests anovulation
Thyroid function tests: Both hypothyroidism and hyperthyroidism cause menstrual irregularity
Prolactin: Elevated prolactin causes anovulation

Second-Line Tests

Follicle-stimulating hormone and luteinizing hormone: High follicle-stimulating hormone suggests ovarian insufficiency; high luteinizing hormone-to-follicle-stimulating hormone ratio suggests polycystic ovary syndrome
Androgens (testosterone, sex hormone-binding globulin): If polycystic ovary syndrome suspected
Anti-Müllerian hormone: Ovarian reserve assessment

If Suspecting Coagulopathy

First-Line Tests

Complete blood count: Platelet count; mean platelet volume
Coagulation studies: Prothrombin time, activated partial thromboplastin time

Second-Line Tests

Von Willebrand factor antigen and activity: Von Willebrand disease is most common inherited bleeding disorder
Factor VIII level: Often reduced in von Willebrand disease
Platelet function tests: If platelet count normal but bleeding symptoms persist

Endometrial Biopsy: When Is It Indicated?

Indications for Endometrial Sampling

All postmenopausal bleeding — regardless of endometrial thickness
Endometrial thickness greater than 4 mm postmenopausal — on transvaginal ultrasound
Women over 45 with abnormal bleeding — to exclude malignancy
Women under 45 with risk factors: obesity, diabetes, polycystic ovary syndrome, chronic anovulation, tamoxifen use, family history of Lynch syndrome
Persistent intermenstrual bleeding — despite normal ultrasound, especially if age over 40
Failed medical management — of abnormal bleeding
Any bleeding on tamoxifen — mandatory investigation

Biopsy Method	Setting	Advantages	Limitations
Pipelle endometrial biopsy	Outpatient, office-based	Quick, inexpensive, no anesthesia, high sensitivity for diffuse pathology	Blind sampling may miss focal lesions (polyps); insufficient sample in 10-15%
Hysteroscopy with directed biopsy	Outpatient or operating theater	Direct visualization, can biopsy specific lesions, therapeutic (polyp removal)	More invasive, requires equipment and expertise, higher cost
Dilatation and curettage	Operating theater, general anesthesia	Comprehensive sampling	Blind procedure, may miss focal lesions, largely replaced by hysteroscopy

Investigation Strategy by Age Group

Age Group	Mandatory Investigations	Consider Adding	Key Concern
Under 40 years	Pregnancy test, infection screening, transvaginal ultrasound if persistent	Hormones if anovulation suspected; coagulation if heavy bleeding since menarche	Pregnancy-related causes, contraceptive issues, infections
40-45 years	Pregnancy test, transvaginal ultrasound, cervical screening	Endometrial biopsy if risk factors or persistent bleeding	Increasing structural pathology risk; consider malignancy if risk factors
Over 45 years (premenopausal)	Pregnancy test, transvaginal ultrasound, endometrial biopsy	Hysteroscopy if focal pathology suspected	Malignancy must be excluded; structural causes common
Postmenopausal	Transvaginal ultrasound, endometrial biopsy	Hysteroscopy if endometrium thickened or sampling inadequate	Endometrial cancer — 10% of postmenopausal bleeding

When to Refer to Specialist

Urgent Referral Indications

Suspected cervical cancer: Visible cervical lesion, especially friable or bleeding on contact
Postmenopausal bleeding with thickened endometrium: Greater than 4 mm or unable to visualize
Abnormal endometrial biopsy: Hyperplasia with atypia, suspected malignancy
Suspected ectopic pregnancy: Positive β-hCG with no intrauterine pregnancy, adnexal mass, or pain
Persistent bleeding despite treatment: Requires further investigation

7. Pattern Recognition and Clinical Decision-Making

Practical algorithms and decision pathways for intermenstrual bleeding

Step 1: Is This Urgent?

Clinical Scenario	Urgency Level	Immediate Action
Heavy bleeding with hemodynamic instability (tachycardia, hypotension, pallor)	EMERGENT	Resuscitate (IV access, fluids, blood products), urgent gynecology consultation, consider surgical intervention
Positive pregnancy test with bleeding and abdominal pain	EMERGENT	Exclude ectopic pregnancy — urgent transvaginal ultrasound, serum β-hCG, prepare for possible surgery
Postmenopausal bleeding	URGENT	Arrange transvaginal ultrasound within 2 weeks, endometrial biopsy, fast-track referral pathway
Visible suspicious cervical lesion	URGENT	Urgent colposcopy referral (within 2 weeks); do NOT take cervical smear — refer directly
Intermenstrual bleeding with pelvic pain and fever	URGENT	Consider pelvic inflammatory disease or septic abortion; take swabs, start empiric antibiotics, consider admission
New intermenstrual bleeding in woman over 40	URGENT	Arrange transvaginal ultrasound; consider endometrial biopsy; gynecology referral if abnormal
Persistent postcoital bleeding	URGENT	Speculum examination, cervical screening if due, colposcopy referral if cervix abnormal or bleeding persists
Breakthrough bleeding on new contraceptive (less than 3 months)	ROUTINE	Reassurance, ensure compliance, exclude pregnancy if pills missed, review in 3 months
Mid-cycle spotting, predictable pattern, young woman	ROUTINE	Likely ovulation bleeding; reassurance; investigate if pattern changes or becomes heavy

Step 2: Initial Assessment Algorithm

First Questions to Answer:

Is she pregnant? → Perform β-hCG test in ALL reproductive-age women
Is she hemodynamically stable? → Check vital signs; resuscitate if unstable
Is she postmenopausal? → If yes, investigate urgently for malignancy
Is there a visible cervical abnormality? → If suspicious lesion, urgent colposcopy referral
Is she on medications that cause bleeding? → Review contraceptives, anticoagulants

Step 3: Algorithm Based on Pregnancy Status

Algorithm A: Pregnancy Test Positive

Clinical Scenario	Most Likely Diagnosis	Action
Light spotting, no pain, closed cervix	Threatened miscarriage or implantation bleeding	Transvaginal ultrasound to confirm viability and location; serial β-hCG if too early to see pregnancy
Bleeding with cramping, open cervix, products visible	Inevitable or incomplete miscarriage	Options: expectant, medical (misoprostol), or surgical management; support and follow-up
Unilateral pelvic pain, bleeding, positive β-hCG, no intrauterine pregnancy on ultrasound	Ectopic pregnancy until proven otherwise	Urgent gynecology review; serial β-hCG; prepare for possible surgical or medical management
Bleeding, very high β-hCG, “snowstorm” appearance on ultrasound	Gestational trophoblastic disease	Specialist referral to gestational trophoblastic disease center; chest radiograph; arrange management

Algorithm B: Pregnancy Test Negative — Premenopausal Woman

Clinical Scenario	Most Likely Diagnosis	Action
Recently started hormonal contraceptive (less than 3 months)	Breakthrough bleeding (iatrogenic)	Reassurance; review compliance; review in 3 months; consider alternative formulation if persistent
Missed contraceptive pills	Estrogen withdrawal bleeding	Advise on correct pill-taking; emergency contraception if unprotected intercourse; exclude pregnancy
Predictable mid-cycle light spotting with mild pelvic discomfort	Ovulation bleeding (physiological)	Reassurance; no investigation needed if pattern consistent and patient reassured
Postcoital bleeding, red granular area around cervical os	Cervical ectropion	Reassurance; ensure cervical screening up to date; treat with cryotherapy or cautery if troublesome
Postcoital bleeding, abnormal cervical appearance	Cervical pathology (dysplasia or cancer)	Urgent colposcopy referral; do NOT take smear if suspicious lesion visible
Irregular bleeding, purulent discharge, pelvic pain, cervical motion tenderness	Pelvic inflammatory disease	Swabs for chlamydia and gonorrhea; empiric antibiotics; partner notification; consider admission if severe
Irregular bleeding, enlarged irregular uterus, heavy periods	Uterine fibroids	Transvaginal ultrasound; consider referral for management if symptomatic
Irregular bleeding, normal examination, ultrasound shows focal endometrial lesion	Endometrial polyp	Hysteroscopy for diagnosis and polypectomy
Irregular bleeding, obesity, hirsutism, irregular cycles, polycystic ovaries	Polycystic ovary syndrome with anovulation	Hormonal management (combined pill, cyclical progestogens); weight management; consider endometrial protection

Algorithm C: Pregnancy Test Negative — Postmenopausal Woman

Clinical Scenario	Most Likely Diagnosis	Action
Thin atrophic vaginal epithelium, spotting, dyspareunia	Atrophic vaginitis	Vaginal estrogen therapy; still requires transvaginal ultrasound to exclude endometrial pathology
Endometrial thickness less than or equal to 4 mm on transvaginal ultrasound	Atrophic endometrium (low malignancy risk)	Reassurance if single episode; consider biopsy if recurrent; treat atrophic vaginitis if present
Endometrial thickness greater than 4 mm on transvaginal ultrasound	Endometrial pathology — polyp, hyperplasia, or carcinoma	Endometrial biopsy mandatory; consider hysteroscopy for focal lesions
Focal endometrial lesion on ultrasound	Endometrial polyp (most likely) or focal pathology	Hysteroscopy with polypectomy and histology
Thickened heterogeneous endometrium, risk factors (obesity, diabetes)	Endometrial hyperplasia or carcinoma	Urgent endometrial biopsy; gynecology oncology referral if malignancy confirmed
On hormone replacement therapy with unscheduled bleeding	Breakthrough bleeding, but must exclude pathology	Transvaginal ultrasound; endometrial biopsy if endometrium thickened or bleeding persists
On tamoxifen with any bleeding	High risk of endometrial pathology (polyp, hyperplasia, cancer)	Mandatory transvaginal ultrasound and endometrial biopsy

Step 4: Age-Based Decision Framework

Under 40 Years

Primary concerns: Pregnancy, contraceptive issues, infections

Malignancy risk: Low (but not zero)

Approach: Pregnancy test, review medications, infection screening, ultrasound if persistent

40-50 Years

Primary concerns: Structural pathology, anovulation, early malignancy

Malignancy risk: Increasing

Approach: Ultrasound for all, lower threshold for endometrial biopsy, especially with risk factors

Over 50 / Postmenopausal

Primary concerns: Malignancy, atrophy

Malignancy risk: High (10% of postmenopausal bleeding is cancer)

Approach: All cases need ultrasound and consideration of biopsy

“What Do I Do If…” Decision Reference

Clinical Situation	Immediate Action	Next Step
Patient is hemodynamically unstable	ABC assessment, IV access, fluid resuscitation, blood transfusion if needed	Urgent gynecology consultation; may need surgical intervention
Pregnancy test positive with pain	Assume ectopic until proven otherwise; urgent transvaginal ultrasound	If no intrauterine pregnancy: serial β-hCG, gynecology review, prepare for intervention
Visible cervical mass or suspicious lesion	Do NOT take cervical smear; document findings	Urgent colposcopy referral (two-week wait pathway)
Postmenopausal bleeding — first episode	Arrange transvaginal ultrasound within 2 weeks	If endometrium greater than 4 mm or unable to visualize: endometrial biopsy
Patient on anticoagulation with bleeding	Check anticoagulation levels (INR if on warfarin); investigate as per standard pathway	Liaise with anticoagulation service; do not assume bleeding is solely due to anticoagulant
Breakthrough bleeding on contraceptive less than 3 months	Reassurance; check compliance; exclude pregnancy if pills missed	Review in 3 months; if persistent, consider different formulation or investigate
Ultrasound shows fibroids	Document size, number, and location (submucosal most relevant to bleeding)	Refer to gynecology if symptomatic; submucosal fibroids may need hysteroscopic resection
Ultrasound shows endometrial polyp	Document size and characteristics	Refer for hysteroscopic polypectomy — both diagnostic and therapeutic
Endometrial biopsy shows hyperplasia without atypia	Progestogen therapy (oral or intrauterine device)	Follow-up biopsy in 3-6 months to confirm regression
Endometrial biopsy shows hyperplasia with atypia	Urgent gynecology oncology referral	Discuss hysterectomy versus progestogen therapy (if fertility desired)
Pipelle biopsy returns “insufficient sample”	Does not exclude pathology	Proceed to hysteroscopy with directed biopsy, especially if postmenopausal or high-risk

Troubleshooting Persistent or Refractory Intermenstrual Bleeding

When Initial Investigations Are Normal but Bleeding Continues

Was the diagnosis correct? Reconsider alternative causes; repeat history and examination
Was the investigation adequate? Pipelle may miss focal lesions — consider hysteroscopy
Was treatment given adequate time? Hormonal treatments may take 3 months to show effect
Is there more than one cause? Multiple pathologies can coexist (e.g., fibroids AND polyp)
Was compliance adequate? For hormonal management, confirm the patient is taking medication correctly
Have you considered chronic endometritis? Often missed; requires endometrial biopsy with plasma cell analysis
Have you considered coagulopathy? Especially if heavy bleeding since menarche
Is specialist review needed? Consider referral if standard approach has not resolved symptoms

8. Clinical Pearls and Pitfalls

Practical wisdom — learn from successes and avoid common mistakes

Must-Know Clinical Pearls

Always test for pregnancy first: Regardless of contraceptive use, sexual history, or patient certainty, a pregnancy test is mandatory in all reproductive-age women with abnormal bleeding. Early ectopic pregnancy can be life-threatening.

Postmenopausal bleeding is cancer until proven otherwise: Approximately 10% of postmenopausal bleeding is due to endometrial carcinoma. Every case requires investigation with transvaginal ultrasound and consideration of endometrial biopsy.

Do NOT take a cervical smear if you see a suspicious lesion: If the cervix looks abnormal (mass, ulcer, friable tissue), refer directly for colposcopy. A smear may miss invasive cancer and delays diagnosis.

Contraceptive breakthrough bleeding is common and usually benign: Up to 50% of women starting hormonal contraception experience breakthrough bleeding in the first 3 months. Reassure, check compliance, and review — but do not ignore persistent bleeding.

Think about the source of bleeding: Confirm the bleeding is genuinely vaginal. Urethral and rectal sources are sometimes misidentified as vaginal bleeding. Ask the patient to observe carefully.

Multiple causes can coexist: A woman can have fibroids AND a polyp, or cervical ectropion AND endometrial pathology. Do not stop investigating after finding one abnormality if symptoms are not explained.

Chronic endometritis is underdiagnosed: Consider this in unexplained intermenstrual bleeding, especially with history of pelvic inflammatory disease, intrauterine procedures, or infertility. Diagnosis requires endometrial biopsy showing plasma cells.

Von Willebrand disease is the most common inherited bleeding disorder: Consider coagulopathy in women with heavy menstrual bleeding since menarche, easy bruising, or family history of bleeding. A normal platelet count does not exclude it.

Critical Pitfalls to Avoid

Assuming young women do not get cancer: While uncommon, cervical and endometrial cancer can occur in younger women. Do not dismiss persistent symptoms because of age alone — investigate appropriately.

Attributing all bleeding to contraceptives without examination: While breakthrough bleeding is common, always perform a speculum examination to visualize the cervix. A visible lesion should not be blamed on the contraceptive.

Reassuring based on a normal ultrasound alone: Ultrasound may miss small polyps, early endometrial pathology, and cervical lesions. A normal ultrasound does not exclude malignancy — clinical suspicion should guide further investigation.

Accepting “insufficient sample” on Pipelle biopsy as reassuring: An inadequate sample does not exclude pathology. If clinical concern is high, proceed to hysteroscopy with directed biopsy.

Ignoring bleeding on anticoagulation: While anticoagulants increase bleeding, they may also unmask underlying pathology. Investigate women on anticoagulation using the same approach as other patients.

Forgetting to ask about tamoxifen: Any bleeding in a woman on tamoxifen requires urgent investigation. Tamoxifen significantly increases the risk of endometrial polyps, hyperplasia, and cancer.

Delaying investigation of postmenopausal bleeding: Even a single episode of postmenopausal bleeding needs investigation. Do not adopt a “wait and see” approach — early endometrial cancer is highly curable.

Missing ectopic pregnancy: Any reproductive-age woman with bleeding and abdominal pain is ectopic until proven otherwise. A ruptured ectopic pregnancy is a surgical emergency. Always check β-hCG.

Key Takeaways

Pregnancy first: Always exclude pregnancy with β-hCG in any reproductive-age woman with abnormal bleeding, regardless of contraceptive use or stated sexual activity.
Age matters: The differential diagnosis and urgency of investigation change significantly with age. Malignancy risk increases with age, particularly after 40 and in postmenopausal women.
Postmenopausal bleeding is urgent: All postmenopausal bleeding requires investigation. Endometrial cancer causes approximately 10% of cases and is curable if detected early.
Examine the cervix: A speculum examination is essential. Do not take a cervical smear if a suspicious lesion is visible — refer directly for colposcopy.
Use the PALM-COEIN framework: Systematically consider both structural (Polyp, Adenomyosis, Leiomyoma, Malignancy) and non-structural (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not classified) causes.
Transvaginal ultrasound is first-line imaging: It assesses endometrial thickness, identifies structural lesions, and guides further investigation. Best performed in the proliferative phase.
Know when to biopsy: Endometrial sampling is indicated for postmenopausal bleeding, women over 45 with abnormal bleeding, thickened endometrium, and those with risk factors for endometrial cancer.
Iatrogenic causes are common: Hormonal contraceptives, anticoagulants, and tamoxifen are frequent causes. Review medications in every patient but do not assume they are the only cause.
Do not stop at the first diagnosis: Multiple pathologies can coexist. If treatment of one condition does not resolve symptoms, look for additional causes.
Consider chronic endometritis: This underdiagnosed condition should be suspected in unexplained intermenstrual bleeding, especially with infertility or history of pelvic infection.

Quick Reference Algorithm

Systematic Approach to Intermenstrual Bleeding:

Pregnancy test — mandatory in all reproductive-age women
Assess stability — resuscitate if hemodynamically unstable
Take a focused history — use the “BLEEDS” mnemonic; identify red flags
Perform examination — including speculum to visualize the cervix
Determine menopausal status — postmenopausal bleeding requires urgent investigation
Review medications — identify contraceptives, anticoagulants, tamoxifen
Arrange appropriate investigations — transvaginal ultrasound for most; infection screening if indicated
Endometrial biopsy when indicated — postmenopausal bleeding, age over 45, risk factors, thickened endometrium
Refer appropriately — urgent colposcopy for suspicious cervix; gynecology for structural pathology or abnormal biopsy
Follow up — ensure symptoms resolve; reinvestigate if bleeding persists despite treatment